sh-Oligopeptide-1 is a cosmetic ingredient, a lab-made copy of human epidermal growth factor (a skin-cell signaling protein), sold in scalp serums, needling solutions and injection mixtures for thinning hair. Its benefit for regrowth rests on thin ground: human hair data come only from small studies of multi-ingredient products, and laboratory and animal work points both ways. Harms reported are mild and mostly tied to delivery; long-term safety is unstudied. (Full Review)

Protocol

At-home topical approach

1–2 mL serum once daily

Thinning areas, dry scalp, evening; at least 16–24 weeks; no standardized dose

Device-assisted microneedling approach

Twice weekly for 20 weeks

Microneedling stamp plus red and blue light with a growth-factor solution (40 sessions)

In-clinic mesotherapy approach

Every 2 weeks for 6 sessions

Shallow scalp injections spaced 0.5–1 cm apart with a 4 mm needle

Time to effect

3–6 months

Visible density change, if any; human studies assessed hair at 20 weeks to 6 months

Success

By 6 months

Measurable rise in density or diameter at marked sites, confirmed by photographs

Duration

4–6 month trial

Without improved density on standardized photos, continued use has no supporting evidence

Benefits

High: Faster healing of chronic skin wounds and burns; better acne-scar repair after laser treatment

Medium: Fewer acne lesions; reduced facial wrinkles; lighter melasma patches; fewer skin reactions to cancer treatment; faster healing of the eye surface

Low: Increased hair density and thickness in thinning hair; less severe mouth sores during cancer treatment

Speculative: Protection from chemotherapy-induced hair loss

Contraindications

Active scalp skin cancer, or skin cancer on the scalp treated within the past 5 years

Current treatment with cancer drugs targeting the epidermal growth factor receptor, unless approved by the treating oncologist

Pregnancy and breastfeeding

Active scalp infection, open wounds or flaring scalp dermatitis

Known hypersensitivity to epidermal growth factor products or their preservatives

Platelet count below 50,000/µL, INR (clotting-time measure) above the therapeutic target, or history of keloids (injection or microneedling only)

Key Interactions

Topical retinoids (tretinoin, adapalene; caution)

Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin; caution with injection or microneedling delivery)

Potent topical corticosteroids (clobetasol, betamethasone; monitor)

Topical minoxidil (monitor)

Copper peptide GHK-Cu and sh-Polypeptides mimicking other growth factors (fibroblast growth factor, insulin-like growth factor 1; monitor)

Microneedling, fractional laser and light therapy (monitor; potentiating)

Ketoconazole shampoo (no known interaction)

Risk & Side Effects

Low: Mild local skin reactions; complications of scalp injection or microneedling; unwanted hair growth outside the treated area; worsening of autoimmune patchy hair loss

Speculative: Paradoxical shedding from a forced hair-cycle shift; promotion of existing skin or other tumors

Monitoring

Marker	Target	Why
Ferritin	70–150 ng/mL	Iron stores support hair growth
TSH	0.5–2.5 mIU/L	Thyroid imbalance causes shedding
25-hydroxyvitamin D	40–60 ng/mL	Deficiency linked to hair loss
Zinc (serum)	90–120 µg/dL	Deficiency causes shedding
Hair density (trichoscopy)	No established target; track change from own baseline at marked sites	Primary regrowth measure
Hair shaft diameter	No established target; track change from own baseline	Thickening often precedes visible density
Hair pull test	2 or fewer hairs from about 60 pulled	Gauges active shedding
Scalp skin examination	No new or changing lesions	Screens for tumors under growth-factor exposure

Cadence: Baseline before starting; photographs and pull test at 8–12 weeks; trichoscopy and photographs every 3 months for the first year; blood tests repeated at 3–6 months only if a deficiency was corrected; scalp skin examination every 12 months

Qualitative Assessment

Visible fullness of the part line and crown in standardized photographs
Amount of hair on the pillow, in the shower drain and on the brush
Scalp comfort: itching, redness, flaking or tenderness after application
Perceived hair thickness and styling volume
Satisfaction with appearance, rated on a simple 0–10 scale at each photo check

sh-Oligopeptide-1 for Hair Regrowth

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment